RightFit
RecruitingPhase not listed

Active Surveillance SNEP Assay Registry Trial for Prostate Cancer

A Multi-center, Prospective Active Surveillance Registry Trial Assessing the Performance of a Non-invasive Immunogenomic Blood Test for Indolent Prostate Cancer Disease Management.

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
40 Years to 80 Years
Sex
Male only
Healthy volunteers
Not accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

  • Procedures mentioned: Blood draws

Only what the study's summary and detailed description on ClinicalTrials.gov say. Time periods may describe the whole study or a part of it — ask the study team what applies to you.

Show the study's own words
  • "A multi-center, prospective active surveillance registry trial assessing the performance of a non-invasive blood test for indolent prostate cancer disease management."
Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

This study checks how well a blood test helps guide care for slow-growing prostate cancer. It is for men ages 40–80 with low-grade prostate cancer who are being closely monitored or plan to have their prostate removed.

A multi-center, prospective active surveillance registry trial assessing the performance of a non-invasive blood test for indolent prostate cancer disease management.

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • Men ages 40–80 who are expected to live at least 10 more years.
  • Any active surveillance plan is accepted. This means closely checking the cancer with regular tests.
  • There are no limits on PSA, a blood marker used to check prostate health.
  • You must fit one of the two groups below.
  • Group 1: You are on active surveillance and have had only one prostate biopsy showing low-grade cancer. A biopsy tests a small tissue sample.
  • Group 1: Your first yearly biopsy is already scheduled within 90 days after joining.
  • Group 2: You were recently diagnosed with low-grade prostate cancer, chose not to use active surveillance, and are scheduled to have your prostate removed within 90 days after joining.

Who can't join

  • You are on watchful waiting: you are expected to live less than 10 more years and do not plan treatment to cure the cancer.
  • You have symptoms or rising PSA, but prostate biopsies have not shown cancer.
  • You have had another type of cancer, except basal cell carcinoma, a type of skin cancer.

Simplified for readability. The official criteria below are what the study team uses.

Official eligibility criteria

Inclusion Criteria * Men between 40-80 of age with at least a 10-year life expectancy * All active surveillance protocols are accepted * No PSA limits Category 1: * Patient is currently on active surveillance with only ONE previous low grade prostate biopsy. * Patient must already be scheduled for their 1st annual biopsy under their active surveillance protocol within 90 days of enrollment date. Category 2: • Patient is recently diagnosed with low grade prostate cancer but has decided against active surveillance and is scheduled for radical prostatectomy within 90 days of enrollment date. Exclusion Criteria: Men on watchful waiting i.e. those with less than 10-year life expectancy with no intent for curative therapy * Men with symptoms or rising PSA who have not been proven to have cancer by tissue biopsy i.e. men with only negative prostate biopsies. * Patients with a history of a different cancer (except basal cell carcinoma)

Study sites (1)

MI